Abbott (NYSE: ABT) released data showing diabetic ketoacidosis remains frequently undetected among people with diabetes, according to studies presented at the American Diabetes Association's Scientific Sessions in June 2026.

The research analyzed over 100,000 people across the U.S. and found that DKA can be difficult to recognize at hospital admission because early symptoms such as nausea, fatigue, and stomach pain overlap with common illnesses. A confirmed DKA diagnosis requires blood tests measuring blood sugar, blood pH, bicarbonate levels, and ketones, which may not be immediately available at admission.

A separate study of over 200,000 people showed DKA hospitalization rates among people with Type 1 diabetes increased approximately 24% between 2017-2024, rising from 50 to 62 cases per 1,000 individuals. The increase was more pronounced in children than adults.

Analysis of nearly 40,000 pediatric hospitalizations revealed DKA drives nearly 60% of all diabetes-related hospitalizations among youth with Type 1 or Type 2 diabetes. Most U.S. hospitalizations among children with diabetes are DKA-related, requiring inpatient care lasting up to one week and costing up to $38,000 per stay.

DKA occurs when the body lacks sufficient insulin and begins breaking down fat for energy, causing ketones to rise to dangerous levels in the blood. The condition can escalate within hours and lead to coma or death if untreated.

"When early symptoms are misattributed, delays in diagnosis are common and often result in lengthy and costly hospitalization," said Kurt Midyett, a pediatric endocrinologist at Saint Luke's Endocrinology Specialists in Kansas City, Missouri.

Abbott announced CE Mark approval for its dual glucose-ketone sensing technology systems, Libre Duo and Libre Duo 10 Day, in May 2026. The company has filed a regulatory submission with the U.S. Food and Drug Administration. The systems are not yet cleared by the FDA or available for sale in the United States.